A deeper understanding of the targets and mechanisms of fast-acting antidepressants, exemplified by ketamine, remains indispensable for better therapeutic strategies and understanding depression. Beyond the canonical neuron-centric NMDAR inhibition hypothesis, brain opioid system and glia-mediated processes are increasingly implicated in ketamine's antidepressant efficacy, yet their precise contributions remain poorly understood. Here, we demonstrate that one major metabolite of ketamine, (2R,6R)-hydroxynorketamine (HNK), selectively targets mu-delta opioid receptor heterodimers ( mu-delta-ORs) on astrocytes. By promoting the formation and/or stabilization of mu-delta-ORs, HNK engages Gs-coupled signaling, elevates intracellular cAMP, phosphorylates CREB (p-CREB) levels and Ca 2+ dynamics in astrocytes, and consequently restores key astrocytic proteins and functions in depression models. Disrupting mu-delta-OR assembly or Gs signaling abolishes HNK-mediated antidepressant responses both in vitro and in vivo. Collectively, astrocytic opioid receptor heterodimers are critical to antidepressant responses and HNK may serve as a prototype compound for targeting astrocyte dysfunction across a wide range of brain disorders.
Yang, S., Wang, L. J., Sun, Y., Ma, X., Rong, Y., Fong, T. H., Li, T., Deng, D., Li, X.-X., Zhang, Z., Liang, Y.-X., Bu, X., Peng, T., Xu, H., Wang, C., Cai, X., zhou, q.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0